PROCESS FOR MANUFACTURING R(-)-NORCARNITINE TERT-BUTYL ESTER

Abstract: Tert-butyl 4-dimethylamino-3(R)-hydroxy butyrate (R(-)-­ norcarnitine tert-butyl ester), a versatile intermediate, useful in the preparation of R(-)-carnitine and derivatives thereof (e.g. alkanoyl R(-)-carnitines) is prepared by converting tert­ butyl-4-chloroacetoacetate in the presence of a mutant of Saccharomices cerevisiae (ATCC 26403) to tert-butyl-4-­ chloro-3(R)-hydroxy butyrate which is epoxidized with silver oxide in a nitrogen atmosphere. The epoxide, which keeps the desired R configuration, is then converted into the final com­ pound by aminating it with dimethylamine in a lower alkanol.

Description: The present invention relates to a process for preparing R(-)-norcarnitine tert-butyl ester (Tert-butyl 4-dimethylamino -3(R)-hydroxy butyrate) having formula (I) EMI1.1 (I) is a useful intermediate in the preparation of R(-)carnitine and R(-) carnitine derivatives, such as alkanoyl R(-)-carnitines, whose various therapeutical utilizations are known. Tert-butyl ester ofnorcarnitine contains an asymmetric carbon atom. This molecular species thus exists in two optically active stereoisomer forms, the R stereoisomer (its configuration is illustrated by formula (I)) and the S stereoisomer (its configuration is illustrated by formula (I')), and in the optically inactive R,S-racemic mixture. Recently, particular emphasis has been placed on the importance of utilizing for therapeutical applications R(-)-carnitine and R(-)-carnitine derivatives exclusively, carefully avoiding the presence of the S stereoisomer. This latter exerts, in fact, an inhibiting action on the R stereoisomer (which is on the other hand the "naturally" occurring carnitine found in muscular tissues and myocardium of mammals). In addition to both chemical and microbiological methods for resolving racemic mixtures which aim at isolating the desired R stercoisomcr from the S stereoisomer, cheniical and microbiological methods have been developed for selectively synthesizing a carnitine precursor which already presents the desired R configuration, typical of the natural carnitine. In the Italian patent application 48504A84 filed on July 4,1984 in the name of the same applicant. of the present application (see also the corresponding: EP application 0169176), tert-butyl ester of R,S-norcarnitine and a process for its preparation have been disclosed and claimed. This product (or, optionally, a derivative thereof) must, therefore, be subjected to the above-mentioned resolution procedures. in order to isolate the desired R isomer from the S isomer. The process of this invention allows R(-)-norcarnitine tert-butyl.ester to be obtained directly and selectively,without attendant formation of the S isomer. Therefore, compound (I) shall be directly utilized for producing R(-)-carnitine or any derivative thereof. The process of the present invention is illustrated by the following reaction scheme: EMI3.1 More.specifically, the process of the present invention comprises the steps of: (1) converting tert-butyl4-.chloro-acetoacetate (II) into tert-butyl-4-chloro-3(R)-hydroxy butyrate (III) in the presence of Saccharomices cerevisiae ATCC 26403; (2) converting (III) into the corresponding epoxide (IV), by keeping a reaction mixture comprising a solution of (III) in an anhydrous organic solvent and silver oxide, at molar ratio (III): Ag2O 1:3, in an atmosphere of a dry inert gas, at the reflux temperature of the mixture, for 40-48 hours; (3) reacting a solution of the epoxide (IV) in a lower alkanol with a solution of dimethylanine in a lower alkancl. at molar ratio (IV): dimethylamine comprised between 1:09 and 1:1.1, keeping the reaction mixture at about 5-300C for about 3-8 hours in an atmosphere of inert gas, thus obtaining (I); and (4) isolating (I) from the reaction mixture of step (3) by concentrating the mixture under vacuum and taking up the residue with a water insoluble solvent, extracting with a diluted acid solution and then alkalinizing to pH about 12, dehydrating the resulting organic phase and removing the organic solvent via distillation under reduced pressure. Preferably, the organic solvent of step (2) is. selected from dimethoxyethane and ethyl ether,the lower alka no.l. of step (3) is methanol and the water-insoluble organic solvent of step (4) is selected from ethyl ether and ethyl acetate. EXAMPLE (1) Preparation of tert-butyl-4-chloro-3(R)-hydroxy butyrate (III) - Surface growth from a week old agar slant of Saccharomices cerevisiae ATCC 26403, grown on the yeast extract-peptone-dextrose fatty acid agar medium (E. Schweizer e H..Bolling, Proc. Nat. Acad. Sci. USA (1970) 67, 660) was suspended in a 0.85% saline solution. One ml portions of this suspension were used to ino culate a 250 ml Erlenmeyer flask (F-l stage) containing 50 ml of the following medium (YEPD-FA): Sucrose . . 20 g Peptone 20 ,g Yeast extract 10 g K2HP04 5 g KH2P04 5 g Myristic acid 0.07 g Palmitic acid 0.07 g Stearic acid 0.07 g Distilled water, q.s. . 1 liter 2 (Sterilized for 15 min at 30 p.s.i., 2,1 Kg/cm ) The flask was incubated at 25"C on a rotary shaker (250 cycles/min - 5 cm radius) for 24 hours, after which this flask served as the inoculum for a 2000 ml Erlenmeyer flask (F-2 stage) containing 500 ml of the same liquid medium (YEPD-FA). After 20 hours of incubation on a rotary shaker, 1.2 grams of tert-butyl -4-chloroacetoacetate (diluted to 3 times its original volume with anhydrous EtOH) was slowly added using a Harvard infusion pump (Model 940) at a rate of 3ml over a 24 hour period. After 24 hours, sucrose was then simultaneously infused into the fermentation medium at a rate of 7.1 ml (30% sucrose solution) over 24 hours. The continuous slow addition of substrate was terminated after a total of 4.8 g of tert-butyl-4-chloroacetoacetate was added (fourth day). However, sucrose was continuously infused into the flask until the fifth day. After 5 days, the content (F-2 stage) was exhaustively extracted with three 400 ml portions of ethyl acetate. The ethyl acetate was dried over Na2S04 and evaporated yielding 3.6 g of an oily residue. The residue was chromatographed over a silica gel (MN-Kieselgel 60) column. The column was eluted with Skelly B-ethyl acetate (8:1) to yield 1.9 g of tert-butyl-4-chloro-3(R) hydroxybutyrate4 D = + 18.09 , (c= 5.1 CHCl3 ). 3 (2) Preparation of tert-butyl R-3,4-epoxybutyrate To a solution of 7.8 g (0.04 moles) of tert-butyl-4-chloro -3(R)-hydroxybutyrate in 80 ml of anhydrous dimethoxyethane,18.4 g ( 0.8 moles) of silver oxide were added under a nitrogen atmosphere. The mixture was kept under stirring overnight at 850C. To the mixture, further 10 g (0.04moles) of silver oxide were added and the resulting mixture was refluxed under stirring overnight. The resulting solution was filtered and the solvent distilled off under reduced pressure (about 50. mm Hg) yielding 5 grams of a yellow liquid corresponding to the title compound. [&alpha;]D25 = + 23 (c 1, CHCl3) NMR CDCl3 #3.2 (m, 1H, -CH-); 2.8 (t, 1H, EMI6.1 2.4 (m, 3H, EMI6.2 1.4 (s, 9H,-(CH ) ). TLC . silica gel Eluent petroleum ether: ethyl acetate 5:1 Gaschromatography Column SE 30 (3%) on 80/100 Chromosorb w AW-DMC' (lenght 1.5 m; inner diameter 4 mm; glas: Column temperature isotherm at 1000C Injector temperature 1400C Detector temperature 1600C (FID) Gas rate N2 50 ml/min Chart speed 0.5 cm/min Retention time tert-butyl-3,4 epoxybutyrate #2 min, tert-butyl 4-chioro, 3( R )-hydroxybutyrat ¯ 4 min (3) Preparation of R(-)-norcarnitine tert-butyl ester A solution of epoxide (1g; 6.3 mmoles) in 3 ml of anhydrous methanol was kept under a nitrogen blanket and cooled to 5-10 C. 680 mg of 39% Me2NH in methanol (5.9 mmoles) were added and the t perature was allowed to raise to 250C, while stirring was continu for 3 hours. The solvent was then evaporated under reduced pressu and an oily product was obtained which was dissolved in 6 ml of ether and subsequently extracted 3 times with 2 ml of cold 5% Hal. Extract's pH was adjusted to 12 with NaOH and the basic solution was extracted 3 times with 3 ml of ethyl acetate, which was then washed with 2 ml H20. The organic phase was dehydrated over Na 2S04 and the solvent distilled off under reduced pressure 700 mg of R(-)-norcarnitine tert-butyl ester were obtained. Yield: 55%. The compound showed RE 0.7 on silica gel plates with CHCl3/MeOH/NH3 80/20t2 and developed with I2; it distilled at 1000C.at 0.5 mm Hg as a colourless liquid which rapidly turned to yellow at room temperature.

Claims: WHAT IS CLATMED IS: 1. A process for preparing tert-butyl 4-dimethylamino-3(R) hydroxy butyrate having formula: EMI9.1 according to the following reaction scheme: EMI9.2 which comprises the steps of: (1) converting tert-butyl-4-chloro-acetoacetate (II) into tert-butyl-4-chloro-3(R)-hydroxy butyrate (III) in the presence of saccharomices cerevisiae ATCC 26403; (2) converting (III) into the corresponding epoxide (IV),by keeping a reaction mixture comprising a solution of (III) in an anhydrous organic solvent and silver oxide, at molar ratio (III): Ag20 1:3, in an atmosphere of a dry inert gas, at the reflux temperature of the mixture, for 40-48 hours; (3) reacting a solution of the epoxide (IV) in a lower alkanol with a solution of dimethylamine in a lower alkanol, at molar ratio (IV): dimethyiamine comprised between 1:a9 and 1:1.1, keeping the reaction mixture at about 5-30 C for about 3-8 hours in an atmosphere of inert gas, thus obtaining (I); and (4) isolating (I) from the reaction mixture of step (3) by concentrating the mixture under vacuum and taking up the residue with a water insoluble solvent, extracting with a diluted acid solution and then alkalinizing to pH about 12,dehydrating the resulting organic phase and removing the organic solvent via distillation under reduced pressure. 2. The process of claim 1, wherein the organic solvent of step (2) is selected from dimethoxyethane and ethyl ether, the lower alkanol of step (3) is methanol and the water-insoluble organic solvent of step (4) is selected from ethyl ether and ethyl acetate.

Inventors: TINTI, MARIA ORNELLA
Applicants: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
Application year: 1986
Main classification: C07C101
IPC codes: C12P7, C07C227, C07D303